NEW YORK (GenomeWeb) – With novel amplification and detection technology, startup Prominex promises fully-automated multiplex molecular point-of-care testing that can provide results in five minutes.
The firm recently raised $4 million in Series A-1 funding and is driving towards launching a sample-in, results-out, CLIA-waived instrument and infectious disease assays in the next three years for an intended market of hospitals, emergency departments, intensive care units, and physician offices.